STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer Academic Article 2016

http://www.tandfonline.com/doi/abs/10.1080/15384101.2016.1245249?journalCode=kccy20

Overview
Additional Document Info
Ver todos

authors

Cuyàs E.
PEREZ SANCHEZ, ALMUDENA
MICOL MOLINA, VICENTE
Menéndez J.A.
Bosch-Barrera J.

publication date

2016

published in

CELL CYCLE Journal